NORVIT indicates Norwegian Vitamin Trial; WENBIT, Western Norway B Vitamin Intervention Trial.
Ebbing M, Bønaa KH, Nygård O, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, Njølstad I, Refsum H, Nilsen DW, Tverdal A, Meyer K, Vollset SE. Cancer Incidence and Mortality After Treatment With Folic Acid and Vitamin B12. JAMA. 2009;302(19):2119–2126. doi:10.1001/jama.2009.1622
Author Affiliations: Department of Heart Disease, Haukeland University Hospital, Bergen, Norway (Drs Ebbing, Nygård, and Nordrehaug); Department of Heart Disease, University Hospital of North Norway, Tromsø (Drs Bønaa and Rasmussen); Departments of Community Medicine (Drs Bønaa, Arnesen, and Njølstad) and Clinical Medicine (Dr Rasmussen), University of Tromsø, Tromsø, Norway; Institute of Medicine, University of Bergen and Haukeland University Hospital, Bergen, Norway (Drs Nygård, Ueland, Nordrehaug, and Nilsen); Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway (Dr Refsum); Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford, England (Dr Refsum); Department of Cardiology, Stavanger University Hospital, Stavanger, Norway (Dr Nilsen); Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway (Drs Tverdal and Vollset); Bevital AS, Bergen, Norway (Dr Meyer); and Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway (Dr Vollset).
Context Recently, concern has been raised about the safety of folic acid, particularly in relation to cancer risk.
Objective To evaluate effects of treatment with B vitamins on cancer outcomes and all-cause mortality in 2 randomized controlled trials.
Design, Setting, and Participants Combined analysis and extended follow-up of participants from 2 randomized, double-blind, placebo-controlled clinical trials (Norwegian Vitamin Trial and Western Norway B Vitamin Intervention Trial). A total of 6837 patients with ischemic heart disease were treated with B vitamins or placebo between 1998 and 2005, and were followed up through December 31, 2007.
Interventions Oral treatment with folic acid (0.8 mg/d) plus vitamin B12 (0.4 mg/d) and vitamin B6 (40 mg/d) (n = 1708); folic acid (0.8 mg/d) plus vitamin B12 (0.4 mg/d) (n = 1703); vitamin B6 alone (40 mg/d) (n = 1705); or placebo (n = 1721).
Main Outcome Measures Cancer incidence, cancer mortality, and all-cause mortality.
Results During study treatment, median serum folate concentration increased more than 6-fold among participants given folic acid. After a median 39 months of treatment and an additional 38 months of posttrial observational follow-up, 341 participants (10.0%) who received folic acid plus vitamin B12 vs 288 participants (8.4%) who did not receive such treatment were diagnosed with cancer (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.03-1.41; P = .02). A total of 136 (4.0%) who received folic acid plus vitamin B12 vs 100 (2.9%) who did not receive such treatment died from cancer (HR, 1.38; 95% CI, 1.07-1.79; P = .01). A total of 548 patients (16.1%) who received folic acid plus vitamin B12 vs 473 (13.8%) who did not receive such treatment died from any cause (HR, 1.18; 95% CI, 1.04-1.33; P = .01). Results were mainly driven by increased lung cancer incidence in participants who received folic acid plus vitamin B12. Vitamin B6 treatment was not associated with any significant effects.
Conclusion Treatment with folic acid plus vitamin B12 was associated with increased cancer outcomes and all-cause mortality in patients with ischemic heart disease in Norway, where there is no folic acid fortification of foods.
Trial Registration clinicaltrials.gov Identifier: NCT00671346
Folate is a B vitamin essential for nucleotide biosynthesis, DNA replication, and methyl group supply, and thus for cell growth and repair.1 Folic acid is the synthetic form of folate used in vitamin supplements and in fortified foods. Most epidemiological studies have found inverse associations between folate intake and risk of colorectal cancer,2 although such associations have been inconsistent or absent for other cancers.3- 8 Experimental evidence suggests that folate deficiency may promote initial stages of carcinogenesis, whereas high doses of folic acid may enhance growth of cancer cells.9,10
Since 1998, many countries, including the United States, have implemented mandatory folic acid fortification of flour and grain products to reduce the risk of neural-tube birth defects.11 In the US population, fortification has resulted in substantial increase in circulating folate12 and unmetabolized folic acid13 concentrations. Recently, concerns have emerged about the safety of folic acid, in particular with respect to cancer risk.1
Folic acid has been used alone or in combination with other B vitamins in a series of homocysteine-lowering trials initiated in patients with cardiovascular disease to assess whether this treatment may reduce cardiovascular outcomes.14 So far, none of the larger trials has reported beneficial effects on primary outcomes.14
In 2 Norwegian homocysteine-lowering trials among patients with ischemic heart disease, there was a statistically nonsignificant increase in cancer incidence in the groups assigned to folic acid treatment.15,16 Our study was performed to explore whether folic acid treatment was associated with cancer outcomes and all-cause mortality after extended follow-up. Because there is no folic acid fortification of foods in Norway, this study population was well suited for such an investigation.
This is a combined analysis of data from 2 randomized, double-blind, placebo-controlled clinical trials (Norwegian Vitamin [NORVIT] trial15 and Western Norway B Vitamin Intervention Trial [WENBIT]16) conducted between 1998 and 2005, and an observational posttrial follow-up through December 31, 2007, with respect to cancer outcomes and all-cause mortality. Details and the primary results of the 2 trials have been reported previously.15,16 The pooling of data is justified by the fact that the 2 trials included similar patients, had identical study design and treatment regimen, had similar follow-up routines, and used the same central laboratory for study-related blood analyses.
The objective of both trials was to assess whether homocysteine-lowering treatment with folic acid and vitamin B12 could improve cardiovascular morbidity and mortality in patients with ischemic heart disease. Patients with known active cancer were excluded, whereas patients with a history of cured cancer were not excluded. All participants gave written informed consent. Participants were randomly assigned to receive a capsule with 1 of the following 4 compositions: (1) folic acid (0.8 mg/d) plus vitamin B12 (cyanocobalamin; 0.4 mg/d) and vitamin B6 (pyridoxine hydrochloride; 40 mg/d); (2) folic acid (0.8 mg/d) plus vitamin B12 (0.4 mg/d); (3) vitamin B6 alone (40 mg/d); or (4) placebo. They were concomitantly requested to abstain from taking over-the-counter supplements containing B vitamins.
Clinical information and blood samples were obtained at baseline, 1 to 2 months after randomization, and at a final study visit in both trials. Adherence was judged by capsule counts and interviews. Analyses of circulating B vitamins, homocysteine and cotinine, and genotyping of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene (NCBI Entrez Gene 4524) 677C>T single-nucleotide polymorphism were performed at the laboratory of Bevital AS, Bergen, Norway, by published methods.17- 20
The NORVIT trial was terminated in March 2004 and the WENBIT in October 2005. When trial results were available, participants were informed by letter that there was no apparent health benefit from the B vitamin intervention.
Participants residing in Norway at the time of their final study visit were included in the posttrial follow-up, which did not imply any continued study treatment, further blood sampling, or personal contact. Our study was approved by the Regional Committee for Medical and Health Research Ethics, the Data Inspectorate, and the Norwegian Directorate of Health.
The primary end points were cancer incidence, cancer mortality, and all-cause mortality through 2007. Data were obtained by linking the unique personal identification numbers to the Cancer Registry of Norway21 and to the Cause of Death Registry at Statistics Norway.22 Malignant neoplasms except nonmelanoma skin cancers were considered, and only the first of new primary cancers after randomization was included. A person was regarded deceased from cancer if the underlying cause of death was coded as International Statistical Classification of Diseases, 10th Revision (ICD-10) codes C00 to C97.
Analyses were conducted among all individuals who participated in the trials. Differences between groups were tested with χ2 test for categorical variables and 1-way analysis of variance, Kruskal-Wallis, or Mann-Whitney U test were used for continuous variables.
We computed the expected numbers of total incident cancers and incidence of the major cancer subtypes in the study population by applying age (5-year age groups) and sex-specific annual national cancer incidence rates for the actual calendar years from the Cancer Registry of Norway.23 The 95% confidence intervals (CIs) for the observed vs expected incidence ratios were computed, assuming that cancer incidence had a Poisson distribution.
Cancer and mortality outcomes were analyzed for groups assigned to folic acid plus vitamin B12 treatment (folic acid groups) vs no folic acid plus vitamin B12 treatment (non–folic acid groups), and for groups assigned to vitamin B6 treatment (vitamin B6 groups) vs no vitamin B6 treatment (non–vitamin B6 groups), according to the 2×2 factorial design. There were no interaction effects between folic acid plus vitamin B12 treatment and vitamin B6 treatment on the primary end points (all P for interaction ≥ .63).
Neither of the 2 trials was originally designed to address cancer risk. By pooling the data and extending the follow-up of both trial populations, we had a statistical power of 61% to detect the observed difference in cancer incidence between the folic acid and non–folic acid groups at a 2-sided statistical significance level of .05.
Person-time was calculated from the date of randomization to the date of event, date of emigration, or December 31, 2007, whichever occurred first. Participants who declined posttrial follow-up were censored at the date of their final study visit.
Survival curves were constructed using the Kaplan-Meier method and differences in survival between groups were analyzed using the log-rank test. Estimates of hazard ratios (HRs) with 95% CIs were obtained by using Cox proportional hazards regression models stratified by trial. Proportional hazards assumptions were tested by Stata’s estat phtest based on Schoenfeld residuals,24 and evidence of nonproportionality was not found.
For the 3 closely associated primary end points and for noncancer mortality, we obtained HRs with 95% CIs. A 2-sided statistical significance level of .05 was applied throughout and reported P values were not adjusted for multiple comparisons.
Because our study was not preplanned, and we performed several outcome analyses, there was an increased risk of type I error. However, to guard against this, for incidence and mortality of cancer subtypes, we reported HRs with 99% CIs.
Effect modifications of folic acid plus vitamin B12 treatment by subgroup indicators were assessed by including the relevant interaction terms in the main effects model. Six predefined participant characteristics were examined for the 3 primary end points across folic acid plus vitamin B12 treatment. Of the resulting 18 comparisons, there was a 60.3% probability that one or several statistically significant P values would appear on the basis of chance alone. No subgroup analyses were performed with respect to vitamin B6 treatment.
To assess separate effects of folic acid treatment and vitamin B12 treatment, we stratified the study population by quartiles of serum folate and serum cobalamin (vitamin B12) measured during study treatment, and estimated HRs for the primary end points across these strata, independently of the random treatment assignment.
We used the statistical software packages SPSS version 15.0 (SPSS Inc, Chicago, Illinois), SAS version 9.2 (SAS Institute, Cary, North Carolina), Stata version 10 (StataCorp LP, College Station, Texas), and S-Plus version 8.0 (TIBCO Software Inc, Palo Alto, California).
The numbers of participants through in-trial and posttrial follow-up are shown in the Figure. A total of 6837 individuals were included in the combined analyses, of whom 6261 (91.6%) participated in posttrial follow-up. Median (interquartile range) duration of extended follow-up through December 31, 2007, was 78 (61-90) months, including median (interquartile range) in-trial follow-up of 39 (31-42) months.
Patient baseline characteristics, risk factor levels, and use of concomitant medications are shown in Table 1. Mean (SD) age was 62.3 (11.0) years and 23.5% of participants were women. The percentage of current smokers (total 39%) was lower in the folic acid groups (38%) than in the non–folic acid groups (41%) (P = .01). Among current smokers, plasma levels of cotinine, a marker of tobacco exposure,19 did not differ across the intervention groups. A total of 297 participants (4.3%) had been registered with cancer before trial entry. The prevalence of TT homozygotes of the MTHFR 677C>T polymorphism was 8.2%, similar to that found in a large sample from the general Norwegian population.25
Adherence, defined as taking at least 80% of the study capsules throughout in-trial follow-up, was 84.7%. eTable 1 shows circulating B vitamin levels at baseline and during study treatment. In the folic acid groups, median serum folate increased from 3.9 to 27.5 ng/mL (to convert to nmol/L, multiply by 2.266) and serum cobalamin from 477 to 761 pg/mL (to convert to pmol/L, multiply by 0.7378) during the intervention. In the vitamin B6 groups, median plasma pyridoxal 5′ phosphate (the active form of vitamin B6) increased from 8.2 to 75.4 ng/mL (to convert to nmol/L, multiply by 4.046).
Individuals with the TT genotype of the MTHFR 677C>T polymorphism had lower median serum folate concentration than those individuals with the CC or CT genotype, both at baseline (17.7% lower; P < .001) and during study treatment (11.7% lower in the folic acid groups and 10.4% lower in the non–folic acid groups, P < .001 and P = .001, respectively).
A total of 629 participants (9.2%) were diagnosed with new cancers during (n = 292) or after (n = 337) the trials. Diagnoses were based on histological, cytological, or other diagnostic examinations in 90.5%, 4.9%, and 4.1% of the incident cases, respectively. Three cases of cancer were based on information from death certificates only.
The total cancer incidence and cancer pattern in the study population were similar to what was expected in the general Norwegian population, except for a 25% higher lung cancer incidence (HR, 1.25; 95% CI, 1.01-1.53) in the study population vs the general population. A total of 496 participants (7.3%) died during the trials and 525 (8.4%) died during posttrial follow-up. Of the total 1021 deaths through December 31, 2007, 236 (23.1%) were classified as cancer deaths and 75 of 236 (31.8%) were lung cancer deaths.
Table 2 shows cancer and mortality outcomes in the 4 intervention groups and the HRs and CIs for the comparisons between folic acid vs non–folic acid groups and between vitamin B6 vs non–vitamin B6 groups. Treatment with folic acid and vitamin B12 was associated with a statistically significant increase in cancer incidence during extended follow-up of both trial populations through December 31, 2007 (folic acid vs non–folic acid groups: HR, 1.21; 95% CI, 1.03-1.41; P = .02). This treatment was also associated with a statistically significant increase in cancer mortality (HR, 1.38; 95% CI, 1.07-1.79; P = .01) and all-cause mortality (HR, 1.18; 95% CI, 1.04-1.33; P = .01).
The cumulative incidence and mortality curves in the eFigure indicate that the increase in cancer incidence, cancer mortality, and all-cause mortality associated with folic acid plus vitamin B12 treatment emerged after approximately 1, 2, or 3 years of follow-up, respectively. Treatment with vitamin B6 was not associated with the primary end points (Table 2 and eFigure).
Adjusting for age (continuous), sex, baseline smoking status, and use of acetylsalicylic acid, or for baseline smoking status alone, did not essentially alter the results. Excluding the 297 participants with registered cancer before trial entry, of whom 23 (7.7%) also had new cancer diagnosis after randomization, or excluding those participants with diagnosed new cancer within 1 year after randomization (n = 97), gave similar results.
When restricting analyses to participants who took study capsules for more than 6 months following randomization (n = 6218, 90.9% of all), HRs for cancer incidence, cancer mortality, and all-cause mortality in the folic acid vs non–folic acid groups increased to 1.27, 1.43, and 1.24, respectively.
Results for the 4 most common cancer subtypes in the study population are shown in Table 2. Estimated HRs for colorectal cancer incidence and colorectal cancer mortality in the folic acid vs non–folic acid groups were close to 1. For the other cancer subtypes, estimated HRs for folic acid vs non–folic acid groups were more than 1, but 99% CIs included the value of 1.
There were 56 cases of lung cancer in the folic acid groups compared with 36 cases in the non–folic acid groups (HR, 1.59; 99% CI, 0.92-2.75). Of all patients diagnosed with lung cancer, 64 (69.6%) were current smokers, 22 (23.9%) were former smokers, and 6 (6.5%) were never smokers at trial entry. After removal of the lung cancer cases, HR for cancer incidence in folic acid vs non–folic acid groups was 1.16 (95% CI, 0.98-1.37).
Table 3 shows the primary end points for folic acid vs non–folic acid groups across patient characteristics. Results were consistent in both trial populations, among patients aged younger than or older than the median (62.5 years), in both sexes, among never and ever smokers, and among patients with baseline serum folate levels of less than or more than the median (3.9 ng/mL) (all P for interaction ≥ .06). HRs for folic acid vs non–folic acid groups were higher among individuals with TT genotype than among those with CC or CT genotypes of the MTHFR 677C>T polymorphism. For cancer mortality, we observed a statistically significant interaction between TT vs CC or CT genotypes and folic acid plus vitamin B12 treatment (P = .03).
eTable 2 shows the primary end points across strata defined by serum folate and serum cobalamin levels measured during study treatment. Participants in the second serum folate quartile (range, 3.81-10.56 ng/mL) or in the second cobalamin quartile (range, 456.4-595.9 pg/mL) had the lowest cancer incidence, cancer mortality, and all-cause mortality through extended follow-up; therefore, quartile 2 was used as the reference category. HRs were statistically significantly higher for participants in the fourth serum folate quartile (>27.66 ng/mL) compared with those in the second folate quartile. There were no such differences across quartiles of serum cobalamin.
We investigated cancer and mortality outcomes after extended follow-up of 6837 individuals who participated in 2 similar randomized B vitamin trials. Study treatment with 0.8 mg/d of folic acid and 0.4 mg/d of vitamin B12 during a median of 39 months was associated with increased cancer incidence and cancer mortality after an additional median of 38 months of posttrial follow-up. These findings were mainly driven by increased lung cancer incidence. Furthermore, folic acid plus vitamin B12 treatment was associated with higher all-cause mortality. The latter finding was driven by the higher cancer mortality, but also by statistically nonsignificant higher noncancer mortality.
Our study is the first to our knowledge to report results from extended follow-up of trial participants after years of treatment with folic acid and other B vitamins. In this large well-described population, adherence was high and corroborated by substantial increase in B vitamin concentrations during study treatment. Loss to follow-up was minimal (1.3%) and ascertainment of outcomes close to complete by linkage to the population-based Cancer Registry23 and Cause of Death Registry.22
Because use of vitamin supplements was modest (23%) at trial entry and there is no folic acid fortification in foods in Norway, baseline serum folate levels were lower than in populations from areas where use of vitamin supplements is more widespread26 and fortification is voluntary27,28 or mandatory.12 The intervention dose of 0.8 mg/d of folic acid was 4 to 6 times higher than the average dose delivered by the mandatory fortification in the United States29 and twice the recommended daily allowance.30 Still, the intervention dose was below the tolerable upper intake level of 1 mg/d as set by the US Institute of Medicine.30 Our findings are therefore relevant across folic acid intake readily obtained from consumption of fortified foods and dietary supplements.
This study has several limitations. First, we do not have data on participants' family history of cancer or on occupational or environmental exposure to cancer-promoting factors. However, due to the large sample size, we expected that these risk factors were evenly distributed across the randomly assigned treatment groups. Second, we do not have information on the use of B vitamin supplements during posttrial follow-up. Because patients were discouraged from such supplement use when trial results were available, we assumed that this was moderate with similar proportions of posttrial B vitamin users across initial treatment groups. Third, the study design implied that all patients assigned to folic acid treatment also received vitamin B12. However, the observed associations between the primary end points and vitamin concentration measured during study treatment were confined to serum folate, suggesting that the adverse effects were mediated by folic acid.
Experimental findings suggest that excess folic acid may stimulate the growth of established neoplasms (ie, the so-called acceleration phenomenon).9,10 There is also the question of potential adverse effects of circulating unmetabolized folic acid.13,31 A recent cross-sectional study32 reported reduced natural killer cell cytotoxicity associated with folic acid in plasma. Thus, folic acid may impair cancer immune defense.32
Epidemiological evidence suggests that large relative increase in the incidence of solid cancers in humans over a short period by chemical causes is unlikely.33 However, it is plausible that folic acid given for a median of 39 months may have influenced growth in cancers that were silent at baseline or during trials,9,10 leading to excess subsequent clinical surfacing and diagnosis in the folic acid groups during extended follow-up.
The observed risk modification by the MTHFR 677C>T polymorphism may reflect its pronounced effect on the metabolic distribution of folate species. In individuals with the TT genotype, more of the intracellular folate is retained as 5,10-methylenetetrahydrofolate needed for nucleotide biosynthesis.34,35 Folic acid treatment may further expand the 5,10-methylenetetrahydrofolate pool and thereby enhance DNA replication and neoplastic growth in these individuals.
The high lung cancer incidence in the study population could readily be explained by the high percentage of former and current smokers. However, the higher incidence observed in the folic acid groups cannot be explained by imbalance in baseline smoking habits, because there were fewer smokers in these groups but no difference in baseline cotinine levels among smokers across the groups. Epidemiological studies have demonstrated no associations between intakes of folate or folic acid and lung cancer risk3,4; therefore, our findings need confirmation in other populations.
Lack of association between folic acid treatment and colorectal cancer outcomes in this study is noteworthy and may reflect the postulated dual effects of folate/folic acid on colorectal carcinogenesis.9,10 For prostate cancer outcomes, estimated HRs were more than 1 for the folic acid vs non–folic acid groups, but although we observed 5 times as many prostate cancer cases (n = 165) as in the Aspirin/Folate Polyp Prevention Study36 (n = 33), we found no statistically significant association between folic acid treatment and these outcomes.
Reports on cancer outcomes from other homocysteine-lowering B vitamin trials do not support our findings.37,38 Notably, these trials used larger folic acid doses and had longer in-trial follow-up than the NORVIT and WENBIT trials. However, 72% of participants in the Heart Outcomes Preventive Evaluation (HOPE) 2 study37 and all participants in the Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)38 resided in North America where fortification had been implemented before trial entry. Therefore, these participants had considerably higher circulating folate concentrations at baseline,37,38 which may have obscured effects from the intervention. Moreover, the HOPE 2 and WAFACS populations had fewer smokers (11.5 and 11.9%, respectively)37,38 than the NORVIT and WENBIT populations did (39.0%). Also, the prevalence of smokers in the general adult US population (approximately 20.9% in 2005)39 is lower than in our study population.
In conclusion, combined analyses and extended follow-up of 2 vitamin B intervention trials among patients with ischemic heart disease in Norway, where there is no folic acid fortification, suggest that treatment with 0.8 mg/d of folic acid was associated with increased cancer incidence, cancer mortality, and all-cause mortality. Our results need confirmation in other populations and underline the call for safety monitoring following the widespread consumption of folic acid from dietary supplements and fortified foods.1,13,40
Corresponding Author: Marta Ebbing, MD, Department of Heart Disease, Haukeland University Hospital, Jonas Liesvei 65, Bergen, Norway 5021 (firstname.lastname@example.org).
Author Contributions: Drs Ebbing and Arnesen had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Ebbing, Bønaa, Nygård, Arnesen, Ueland, Nordrehaug, Rasmussen, Refsum, Nilsen, Vollset.
Acquisition of data: Ebbing, Bønaa, Nygård, Arnesen, Ueland, Rasmussen, Njølstad, Nilsen, Tverdal, Meyer, Vollset.
Analysis and interpretation of data: Ebbing, Bønaa, Nygård, Arnesen, Ueland, Nordrehaug, Rasmussen, Njølstad, Refsum, Tverdal, Meyer, Vollset.
Drafting of the manuscript: Ebbing.
Critical revision of the manuscript for important intellectual content: Ebbing, Bønaa, Nygård, Arnesen, Ueland, Nordrehaug, Rasmussen, Njølstad, Refsum, Nilsen, Tverdal, Meyer, Vollset.
Statistical analysis: Ebbing, Arnesen, Tverdal, Vollset.
Obtained funding: Bønaa, Nygård, Ueland, Nordrehaug, Rasmussen, Refsum, Nilsen, Vollset.
Administrative, technical, or material support: Ebbing, Bønaa, Nygård, Arnesen, Ueland, Nordrehaug, Rasmussen, Refsum, Nilsen, Vollset.
Study supervision: Bønaa, Nygård, Arnesen, Ueland, Nordrehaug, Rasmussen, Nilsen, Vollset.
Financial Disclosures: Dr Meyer is employed at the laboratory of Bevital AS, Bergen, Norway. No other authors reported any conflicts of interest or financial disclosures.
NORVIT Steering Committee: Knut Rasmussen, MD, PhD (chair), Kaare Harald Bønaa, MD, PhD (principal investigator), Egil Arnesen, MD, Inger Njølstad, MD, PhD, Aage Tverdal, PhD, Jan Erik Nordrehaug, MD, PhD, Per Magne Ueland, MD, PhD.
WENBIT Steering Committee: Ottar Nygård MD, PhD (chair), Per Magne Ueland, MD, PhD, Jan Erik Nordrehaug, MD, PhD, Helga Refsum, Dennis W. Nilsen, MD, PhD, Stein Emil Vollset, MD, DrPH.
Funding/Support: The NORVIT and WENBIT trials were funded by the Advanced Research Program and Research Council of Norway; the Norwegian Foundation for Health and Rehabilitation; The Norwegian Council on Cardiovascular Disease; the Norwegian Heart and Lung Patient Organization; the Norwegian Red Cross; the Northern Norway Regional Health Authority; the Western Norway Regional Health Authority; the Norwegian Ministry of Health and Care Services; the University of Tromsø, Tromsø, Norway; the University of Bergen, Bergen, Norway; Department of Heart Disease at Haukeland University Hospital, Bergen, Norway; the Foundation to Promote Research Into Functional Vitamin B12 Deficiency, Bergen, Norway; by an unrestricted private donation; and by Alpharma Inc, Copenhagen, Denmark, who provided study medication. The posttrial follow-up was supported by the Norwegian Foundation for Health and Rehabilitation; Department of Heart Disease at Haukeland University Hospital, Bergen, Norway; the University of Tromsø, Tromsø, Norway; and by the University of Bergen, Bergen, Norway.
Role of the Sponsors: The main sponsors were nonprofit organizations with no participating role in the trials. Alpharma Inc provided the study capsules, generated the randomization sequence and concealed the randomization code, free of charge, and rendered a limited grant to finance the initial phase of the trials. However, the company had no role in the design and conduct of the trials or the current study; or in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. Dr Ebbing had full access to all data at the end of the study and had the final responsibility for the decision to submit for publication.
Disclaimer: Some of the data in this article are from the Cancer Registry of Norway. The Cancer Registry of Norway is not responsible for the analysis or interpretation of the data presented.
Additional Contributions: We thank the recruiting physicians, the study nurses, laboratory personnel, and other coworkers. In addition, we thank all 6837 participants for their time and motivation.